复星医药卖资产保利润,创新转型持续推进

览富财经
Sep 29

出品:山西晚报·刻度财经让主业收入重回增长已经成为复星医药目前最棘手的问题。复星医药在肿瘤、免疫炎症等核心治疗领域统治力似乎有所下降。8月26日,这家医药行业龙头发布了2025年半年报。财报显示,2025年上半年,复星医药整体营收195.14亿元,同比微降4.63%;归母净利润17.02亿元,同比增长38.96%,但扣非净利润 9.61亿元,同比下降23.39%。报告期内,三大核心业务板块(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10